Navigation Links
Making personalized lung cancer therapy a reality in Europe
Date:4/30/2010

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work, a leading expert said today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

Prof Robert Pirker of the Medical University of Vienna said that personalized therapy, in which treatment is based on the characteristics of an individual patient's tumor, promised to improve outcomes for patients, as well as being more cost-effective and less toxic than existing treatments.

"Recently, oral treatment with the targeted drug gefitinib was shown to be superior with regard to progression-free survival compared to treatment with up to six cycles of first-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) who have mutations in their tumors that activate a cell-surface molecule called epidermal growth factor receptor (EGFR)," Prof Pirker said.

This finding led to the approval of this drug in Europe in 2009 --but only for treating patients whose tumors carry these mutations.

"Before we can offer patients gefitinib, the presence of these mutations in tumor cells has to be clearly demonstrated," he explained.

In order to achieve this, doctors must perform a molecular analysis of tumor material from biopsies. "This will benefit patients, but it changes the whole diagnostic workup and requires some change in the thinking of oncologists, including closer co-operation between the various disciplines: interventional pulmonologists, pathologists, biologists, oncologists," he said.

Scientists around the globe are currently probing the genetics of cancers with the aim of identifying new targets for personalized treatment. These projects, such as the International Cancer Genome Consortium, mean that testing for mutations in tumors will become routine.

Eventually, tissue sampling to allow this kind of mutation testing will become standard in Europe, Prof Pirker said. But currently, there are obstacles preventing it from becoming more widespread.

"The obstacles include the fact that too few doctors trained in invasive tumor sampling, that mutation analysis not yet readily available, and that there are reimbursement issues which might vary from country to country," he said.

If these obstacles can be overcome, and more doctors are trained in taking lung cancer biopsies, more patients will be able to be treated with oral gefitinib, and the discovery of other new therapeutic targets will be accelerated," he said.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Making its predators tremble: Multiple defenses act synergistically in aspen
2. National Honor to History-Making Undersea Explorer
3. Making the blind see: Gene therapy restores vision in mice
4. The formula for making teeth will soon be found
5. Texas Childrens discharges history-making patient
6. Making the case for the social sciences
7. Scientists hope to end sleeping sickness by making parasite that causes it self-destruct
8. To a mosquito, matchmaking means singing in perfect harmony
9. Bacteria provide new insights into human decision making
10. Physical education teaching staff play key role in making you like sport
11. A major step in making better stem cells from adult tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
Breaking Biology News(10 mins):
(Date:12/4/2016)... ... December 02, 2016 , ... ... -operated small businesses in federally funded research and development is welcome news for ... optics and photonics . , As part of the National Defense Authorization Act ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of ... lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland from ... disc in Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic ...
(Date:12/2/2016)... , Dec. 2, 2016 CytRx Corporation ... development company specializing in oncology, today announced the appointment ... sarcoma surgeon, industry consultant, and private healthcare investor, to ... a healthcare leader with clinical and strategic experience at ... CytRx,s Chairman and CEO. "As one of the world,s ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... pneumatic tube systems for North American hospitals, will present its chain-of-custody solution for ... and Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a ...
Breaking Biology Technology: